March 12, 2020 10:23 AM EDT
News Briefing

Cure­Vac founder back at the helm; Mer­ck ex­tends im­munomod­u­la­to­ry drug dis­cov­ery pro­gram with Sutro

Amber Tong

→ Daniel Menichel­la, the CEO of Cure­Vac and the face of its re­cent en­deav­ors to de­vel­op an mR­NA vac­cine against Covid-19, is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Chron­ic care start­up Oma­da Health files to go pub­lic

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times